| Mauro, Francesca Romana |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL) |
|
|
| Active, not recruiting | 3 | 897 | Europe, RoW | Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro | German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche | Chronic Lymphoid Leukemia | 09/27 | 09/27 | | |
NCT02232386 / 2014-002714-23: Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia |
|
|
| Completed | 2 | 156 | Europe | Ibrutinib, Rituximab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Lymphocyte Leukemia, Adult Patients | 04/18 | 04/24 | | |
| Completed | 2 | 77 | Europe | Venetoclax, Rituximab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Myeloid Leukemia | 09/21 | 05/23 | | |
NCT02388048 / 2015-000684-13: Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia |
|
|
| Completed | 2 | 19 | Europe | Ibrutinib + ofatumumab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Leukemia, Lymphoblastic, Chronic | 04/24 | 04/24 | | |
VIS, NCT05478512 / 2022-002579-12: Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL |
|
|
| Recruiting | 2 | 78 | Europe | VenObi+Ven or VenObi+VenZan | Gruppo Italiano Malattie EMatologiche dell'Adulto, BeiGene, Roche, Fondazione GIMEMA Franco Mandelli Onlus | High Risk CLL, Chronic Lymphocytic Leukemia | 05/26 | 07/27 | | |
GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy |
|
|
| Recruiting | N/A | 321 | Europe | Venetoclax | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia | 01/23 | 10/25 | | |
| Recruiting | N/A | 190 | Europe | acalabrutinib, Calquence | AstraZeneca, Yghea | Chronic Lymphocytic Leukemia | 02/30 | 02/30 | | |
CLL2423, NCT05803395: Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy. |
|
|
| Recruiting | N/A | 954 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Italiana Linfomi | Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19 | 09/24 | 09/24 | | |
